<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0707245487
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2018
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        ZORON 2MG/ML INJECTION
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        ONDANSETRON
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        2
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intramuscular and intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Solution for injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        2
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Ampoule
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        48
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        91.95
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Jamjoom Pharmaceuticals Factory Company" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Jamjoom Pharmaceuticals Factory Company
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 394]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            JAMJOOM PHARMACEUTICALS CO. LTD.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Jamjoom Pharmaceuticals Factory  Company
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        A04AA01 
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Zoron&trade; injection contains a medicine called ondansetron. This<br />belongs to a group of medicines called anti-emetics.<br />Zoron&trade; injection is used for:<br />&bull; preventing nausea and vomiting caused by chemotherapy (in adults<br />and children) or radiotherapy for cancer (adults only)<br />&bull; preventing nausea and vomiting after surgery.<br />Ask your doctor or pharmacist if you would like any further<br />explanation about these uses.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Do not have Zoron&trade; injection if:<br />&bull; you are taking apomorphine (used to treat Parkinson&rsquo;s disease)<br />&bull; you are allergic (hypersensitive) to ondansetron or any of the other<br />ingredients in Zoron&trade; injection (listed in Section 6).<br />If you are not sure, talk to your doctor or pharmacist before having<br />Zoron&trade; injection.<br />Warnings and precautions<br />Check with your doctor or pharmacist before taking Zoron&trade;<br />injection if:<br />&bull; you have ever had heart problems (e.g. congestive heart failure<br />which causes shortness of breath and swollen ankles)<br />&bull; you have an uneven heart beat (arrhythmias)<br />&bull; you are allergic to medicines similar to ondansetron, such as<br />granisetron or palonosetron<br />&bull; you have liver problems<br />&bull; you have a blockage in your gut<br />&bull; you have problems with the levels of salts in your blood, such as<br />potassium, sodium and magnesium.<br />If you are not sure if any of the above apply to you, talk to your<br />doctor or pharmacist before having Zoron&trade; injection.<br />Other medicines and Zoron&trade;<br />Please tell your doctor or pharmacist if you are taking or have<br />recently taken or might take any other medicines. This includes<br />medicines that you buy without a prescription and herbal medicines.<br />This is because Zoron&trade; can affect the way some medicines work.<br />Also some other medicines can affect the way Zoron&trade; works.<br />In particular, tell your doctor, nurse or pharmacist if you are taking<br />any of the following medicines:<br />&bull; carbamazepine or phenytoin used to treat epilepsy<br />&bull; rifampicin used to treat infections such as tuberculosis (TB)<br />&bull; antibiotics such as erythromycin or ketoconazole<br />&bull; anti-arrhythmic medicines used to treat an uneven heart beat<br />&bull; beta-blocker medicines used to treat certain heart or eye problems,<br />anxiety or prevent migraines<br />&bull; tramadol, a pain killer<br />&bull; medicines that affect the heart (such as haloperidol or methadone)<br />&bull; cancer medicines (especially anthracyclines and trastuzumab).<br />&bull; SSRIs (selective serotonin reuptake inhibitors) used to treat<br />depression and/or anxiety including fluoxetine, paroxetine, sertraline,<br />fluvoxamine, citalopram, escitalopram<br />&bull; SNRIs (serotonin noradrenaline reuptake inhibitors) used to treat<br />depression and/or anxiety including venlafaxine, duloxetine.<br />If you are not sure if any of the above applies to you, talk to your<br />doctor, nurse or pharmacist before having Zoron&trade; injection.<br />Zoron&trade; injection should not be given in the same syringe or<br />infusion (drip) as any other medication.<br />Pregnancy and breast-feeding<br />It is not known if Zoron&trade; is safe during pregnancy. If you are<br />pregnant, think you are pregnant or are planning to have a baby, ask<br />your doctor or pharmacist for advice before taking Zoron&trade;<br />injection.<br />Do not breast-feed if you are have Zoron&trade;. This is because small<br />amounts pass into the mother&rsquo;s milk. Ask your doctor for advice.<br />Important information about some of the ingredients of Zoron&trade;<br />injection<br />This medicine contains sodium citrate and sodium chloride.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Zoron&trade; injection is normally given by a nurse or doctor. The dose<br />you have been prescribed will depend on the treatment you are<br />having.<br />To prevent nausea and vomiting from chemotherapy or<br />radiotherapy in adults<br />On the day of chemotherapy or radiotherapy<br />&bull; the usual adult dose is 8 mg given by a slow injection into your<br />vein or muscle, just before your treatment, and another 8 mg twelve<br />hours later. After chemotherapy, your medicine will usually be given<br />by mouth as an 8 mg Zoron&trade; tablet.<br />On the following days<br />&bull; the usual adult dose is one 8 mg tablet twice a day<br />&bull; this may be given for up to 5 days.<br />If your chemotherapy or radiotherapy is likely to cause severe<br />nausea and vomiting, you may be given more than the usual dose of<br />Zoron&trade;. Your doctor will decide this.<br />To prevent nausea and vomiting from chemotherapy in children<br />aged over 6 months and adolescents<br />The doctor will decide the dose depending on the child&rsquo;s size (body<br />surface area) or weight.<br />On the day of chemotherapy<br />&bull; the first dose is given by an injection into the vein, just before your<br />child&rsquo;s treatment. After chemotherapy, your child&rsquo;s medicine will<br />usually be given by mouth twelve hours later, as ondansetron syrup<br />or a ondansetron tablet.<br />On the following days<br />&bull; 2.5 ml (2 mg) syrup twice a day for small children and those<br />weighing 10 kg or less<br />&bull; one 4 mg tablet or 5 ml (4 mg) syrup twice a day for larger children<br />and those weighing more than 10 kg<br />&bull; two 4 mg tablets or 10 ml (8 mg) syrup twice a day for teenagers<br />(or those with a large body surface area)<br />&bull; these doses can be given for up to five days.</p><p>To prevent and treat nausea and vomiting after an operation<br />Adult:<br />&bull; The usual dose for adults is 4 mg given by a slow injection into<br />your vein or an injection into your muscle. For prevention, this will<br />be given just before your operation.<br />Children:<br />&bull; For children aged over 1 month and adolescents the doctor will<br />decide the dose. The maximum dose is 4 mg given as a slow<br />injection into the vein. For prevention, this will be given just before<br />the operation.<br />Patients with moderate or severe liver problems<br />The total daily dose should not be more than 8 mg.<br />If you keep feeling or being sick<br />Zoron&trade; injection should start to work soon after having the<br />injection. If you continue to be sick or feel sick, tell your doctor or<br />nurse.<br />If you have more Zoron&trade; injection than you should<br />Your doctor or nurse will give you Zoron&trade; injection so it is unlikely<br />that you will receive too much. If you think you have been given too<br />much or have missed a dose, tell your doctor or nurse.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, Zoron&trade; injection can cause side effects,<br />although not everybody gets them.<br />Allergic reactions<br />If you have an allergic reaction, tell your doctor or a member of the<br />medical staff straight away. The signs may include:<br />&bull; sudden wheezing and chest pain or chest tightness<br />&bull; swelling of your eyelids, face, lips, mouth or tongue<br />&bull; skin rash - red spots or lumps under your skin (hives) anywhere on<br />your body<br />&bull; collapse.<br />Other side effects include:<br />Very common (affects more than 1 in 10 people)<br />&bull; headache.<br />Common (affects less than 1 in 10 people)<br />&bull; a feeling of warmth or flushing<br />&bull; constipation<br />&bull; changes to liver function test results (if you take Zoron&trade; injection<br />with a medicine called cisplatin, otherwise this side effect is<br />uncommon).<br />&bull; irritation and redness at the site of injection.<br />Uncommon (affects less than 1 in 100 people)<br />&bull; hiccups &bull; low blood pressure, which can make you feel faint or<br />dizzy<br />&bull; uneven heart beat &bull; chest pain &bull; fits &bull; unusual body movements or<br />shaking.<br />Rare (affects less than 1 in 1,000 people)<br />&bull; feeling dizzy or light headed &bull; blurred vision<br />&bull; disturbance in heart rhythm (sometimes causing a sudden loss of<br />consciousness)<br />Very rare (affects less than 1 in 10,000 people)<br />&bull; poor vision or temporary loss of eyesight, which usually comes<br />back within 20 minutes.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&bull; Keep out of the reach and sight of children.<br />&bull; Do not store above 30 &deg;C. Protect from light.<br />&bull; When Zoron&trade; injection is diluted in intravenous fluids:<br />- it must be stored at 2-8&deg;C for not more than 24 hours<br />- it does not need to be protected from light during infusion.<br />&bull; Do not use Zoron&trade; injection after the expiry date which is stated<br />on the pack and ampoule after &lsquo;EXP&rsquo;.<br />&bull; Do not throw away any medicines via wastewater or household<br />waste. Ask your pharmacist how to throw away medicines you no<br />longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&bull; The active ingredient is ondansetron.<br />Each 2 ml Zoron&trade; injection ampoule contains 4 mg ondansetron as<br />ondansetron hydrochloride dihydrate.<br />Each 4 ml Zoron&trade; injection ampoule contains 8 mg ondansetron as<br />ondansetron hydrochloride dihydrate.<br />&bull; The other ingredients are citric acid monohydrate, sodium citrate,<br />sodium chloride (9 mg/ml) and water for injection.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Zoron™ injection is a clear colorless solution.
Zoron™ injection is available in:
• 2 ml (4 mg) glass ampoules.
• 4 ml (8 mg) glass ampoules.
Packed in boxes of 5 ampoules.
Not all packs may be marketed.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Jamjoom Pharmaceuticals Co., Jeddah, Saudi Arabia.<br />Tel: +966-12-6081111, Fax: +966-12-6081222.<br />Website: www.jamjoompharma.com<br />To report any side effect(s):<br />&bull; Saudi Arabia:<br />The National Pharmacovigilance and Drug Safety Centre (NPC)<br />Fax: +966-11-205-7662<br />Call NPC at +966-11-2038222,<br />Exts: 2317-2356-2353-2354-2334-2340.<br />Toll free phone: 8002490000<br />E-mail: npc.drug@sfda.gov.sa<br />Website: www.sfda.gov.sa/npc<br />&bull; Other GCC States:<br />&minus; Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                12/2015
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>&nbsp;</p><p>1. ما هي حقن زورون&trade; و ما هي دواعي استعمالها</p><p>&nbsp;</p><p>تحتوي حقن زورون&trade; على عقار يسمى أوندانسيترون. و ينتمي إلى مجموعة عقاقيرية تعرف بمضادات التقيؤ.</p><p>تستعمل حقن زورون&trade; للآتي:</p><p>&bull; لمنع الغثيان والقيء الناتجين عن العلاج الكيميائي (في البالغين والأطفال) أو العلاج بالإشعاع لدى مرضى السرطان (للبالغين فقط)</p><p>&bull; لمنع الغثيان والقيء بعد الجراحة.</p><p>إسأل طبيبك أو الصيدلي إذا أردت أي استفسارات أخرى حول هذه الاستعمالات.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>&nbsp;</p><p>2. قبل أن تستخدم حقن زورون&trade;</p><p>&nbsp;</p><p>لا تستخدم حقن زورون&trade; إذا:</p><p>&bull; كنت تستخدم عقار الأپومورفين (يستخدم في علاج مرض پاركنسون)</p><p>&bull; كانت لديك حساسية من الأوندانسيترون أو أي من المكونات الأخرى في حقن</p><p>زورون&trade; (المدرجة في فقرة 6).</p><p>إذا لم تكن متأكدا، تحدث مع طبيبك أو الصيدلي قبل إستخدام حقن زورون&trade;.</p><p>&nbsp;</p><p>التحذيرات والاحتياطات</p><p>إستشر طبيبك أو الصيدلي قبل إستخدام حقن زورون&trade; إذا:</p><p>&bull; كنت تعاني أو عانيت في أى وقت مضى من مشاكل قلبية (مثل قصور القلب الاحتقاني الذي يسبب ضيق في التنفس وتورم الكاحلين)</p><p>&bull; لديك ضربات قلب غير منتظمة (عدم انتظام ضربات القلب)</p><p>&bull; كان لديك حساسية من الأدوية المماثلة لأوندانسيترون، مثل غرانيسترون أو بالونيسترون</p><p>&bull; كان لديك مشاكل في الكبد</p><p>&bull; كنت تعاني من انسداد في الأمعاء</p><p>&bull; كان لديك مشاكل مع مستويات الأملاح في الدم، مثل البوتاسيوم والصوديوم والماغنيسيوم.</p><p>إذا لم تكن متأكدا إذا كان أي من أعلاه ينطبق عليك، فتحدث مع طبيبك أو الصيدلي قبل إستخدام حقن زورون&trade;.</p><p>&nbsp;</p><p>الأدوية الأخرى و زورون&trade;</p><p>فضلاً أخبر طبيبك أو الصيدلي إذا كنت تتناول أو تناولت مؤخراً أو قد تتناول أى أدوية أخرى. وهذا يشمل الأدوية التي تشتريها بدون وصفة طبية والأدوية العشبية. وذلك لأن زورون&trade; قد يؤثرعلى طريقة عمل بعض الأدوية. و أيضاً بعض الأدوية الأخرى يمكن أن تؤثر على طريقة عمل زورون&trade;.</p><p>&nbsp;</p><p>على وجه الخصوص، أخبر طبيبك أو الصيدلي إذا كنت تتناول أي من الأدوية التالية:</p><p>&bull; كاربامازپين أو فينيتوين و كلاهما يستخدم لعلاج الصرع</p><p>&bull; ريفامپيسين و يستخدم لعلاج العدوي مثل السل</p><p>&bull; المضادات الحيوية مثل الاريثروميسين أو الكيتوكونازول</p><p>&bull; الأدوية المنظمة لضربات القلب و تستخدم لعلاج ضربات القلب الغير منتظمة</p><p>&bull; الأدوية حاصرات بيتا التي تستخدم لعلاج مشاكل معينة في القلب أو في العين، القلق أو منع الصداع النصفي</p><p>&bull; ترامادول، وهو مسكن قوى للآلام</p><p>&bull; الأدوية التي تؤثر على القلب (مثل هالوبيريدول أو الميثادون)</p><p>&bull; أدوية السرطان (خاصة&nbsp; أنثراسيكلين وتراستوزوماب).</p><p>&bull; مثبطات امتصاص السيروتونين الانتقائية (SSRIs) المستخدمة لعلاج الاكتئاب و / أو القلق بما في ذلك فلوكستين، بارواكسيتين، سيرترالين، فلوفوكسامين، سيتالوبرام، إسيتالوبرام</p><p>&bull; مثبطات امتصاص سيروتونين نورادرينالين (SNRIs) المستخدمة لعلاج الاكتئاب و / أو القلق بما في ذلك الفينلافاكسين، دولوكستين.</p><p>إذا لم تكن متأكدا مما إذا كان أي من أعلاه ينطبق عليك، فتحدث مع طبيبك، الممرضة أو الصيدلي قبل إستخدام حقن زورون&trade;.</p><p>لا يجوز إعطاء حقن زورون&trade; بنفس المحقنة أو جهاز التسريب (التنقيط) لأي عقار آخر.</p><p>&nbsp;</p><p>الحمل و الرضاعة</p><p>من غير المعروف ما إذا كان زورون&trade; آمن أثناء الحمل. إذا كنت حامل، تعتقدين أنك حامل أو تخططين لإنجاب طفل، استشيري طبيبك أو الصيدلي قبل إستخدام حقن زورون&trade;.</p><p>لا تقومي بالإرضاع إذا كنت تستخدمين زورون&trade; . وذلك لأن كميات صغيرة تنتقل عبر حليب الأم. استشيري طبيبك للحصول على النصيحة.</p><p>&nbsp;</p><p>معلومات هامة حول بعض مكونات حقن زورون&trade;</p><p>هذا الدواء يحتوي على سترات الصوديوم و كلوريد الصوديوم.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>&nbsp;</p><p>3. كيف تستخدم حقن زورون&trade;</p><p>&nbsp;</p><p>عادة تعطى حقن زورون&trade; من قبل الممرضة أو الطبيب. الجرعة التي تم وصفها لك تعتمد على الخطة العلاجية لحالتك.</p><p>&nbsp;</p><p>للوقاية من الغثيان والقىء الناتجين عن العلاج الكيميائي أو العلاج بالإشعاع في البالغين</p><p>في يوم العلاج الكيميائي أو العلاج بالإشعاع</p><p>&bull; الجرعة المعتادة للبالغين هي 8 ملجم تعطى عن طريق الحقن البطيء في الوريد أو في العضلات، قبل المعالجة مباشرة، تعقبها 8 ملجم أخرى بعد اثني عشر ساعة . بعد العلاج الكيميائي، عادة ما يتم إعطاء الدواء عن طريق الفم 8 ملجم أقراص</p><p>زورون&trade;.</p><p>&nbsp;</p><p>في الأيام التالية</p><p>&bull; الجرعة المعتادة للبالغين هي قرص 8 ملجم مرتين يومياً</p><p>&bull; يمكن إعطاء هذه الجرعات لمدة تصل إلى خمسة أيام.</p><p>&nbsp;</p><p>إذا كان من المرجح أن يسبب علاجك الكيميائي أو العلاج بالإشعاع غثيان شديد وقيء، فقد تعطى أكثر من الجرعة المعتادة من زورون&trade;. سوف يقرر طبيبك ذلك.</p><p>&nbsp;</p><p>لمنع الغثيان والقيء من العلاج الكيميائي في الذين تزيد أعمارهم عن 6 أشهر والمراهقين:</p><p>الطبيب سوف يقرر الجرعة تبعا لحجم الطفل (مساحة سطح الجسم) أو الوزن.</p><p>&nbsp;</p><p>في يوم العلاج الكيميائي</p><p>&bull; يتم إعطاء الجرعة الأولى عن طريق الحقن في الوريد، قبل علاج طفلك مباشرة.</p><p>بعد العلاج الكيميائي، عادة ما يتم إعطاء الدواء لطفلك عن طريق الفم بعد اثني عشر ساعة، كشراب أوندانسيترون أو أقراص أوندانسيترون.</p><p>في الأيام التالية</p><p>&bull; 2.5 مل (2 ملجم) شراب مرتين يوميا للأطفال الصغار و الذين يكون وزنهم 10 كجم أو أقل</p><p>&bull; قرص واحد 4 ملجم&nbsp; أو 5 مل (4 ملجم) شراب مرتين يوميا للأطفال الأكبر و الذين يزيد وزنهم عن 10 كجم</p><p>&bull; قرصين 4 ملجم أو 10 مل (8 ملجم) شراب مرتين يوميا للمراهقين (أو هؤلاء الذين لهم مساحة سطح جسم كبيرة)</p><p>&bull; يمكن إعطاء هذه الجرعات لمدة تصل إلى خمسة أيام.</p><p>&nbsp;</p><p>للوقاية علاج الغثيان والقىء بعد العمليات</p><p>البالغين:</p><p>&bull; الجرعة المعتادة للبالغين هي 4 ملجم تعطى عن طريق الحقن البطيء في الوريد أو الحقن في العضلات . للوقاية، ستعطى هذه الجرعة قبل العملية مباشرة.</p><p>&nbsp;</p><p>الأطفال:</p><p>&bull; بالنسبة للأطفال الذين تزيد أعمارهم عن شهر والمراهقين سوف يقرر الطبيب الجرعة. الجرعة القصوى هي 4 ملجم تعطى كحقن بطيئة في الوريد. للوقاية، ستعطى هذه الجرعة قبل العملية مباشرة.</p><p>&nbsp;</p><p>المرضى الذين يعانون من مشاكل في الكبد معتدلة أو شديدة</p><p>الجرعة الإجمالية اليومية يجب ألا تتعدى 8 ملجم.</p><p>&nbsp;</p><p>اذا ما استمر الشعور بالغثيان أو القئ</p><p>يجب أن تبدأ حقن زورون&trade; بالعمل بعد وقت قصير من أخذ الحقنة. إذا كنت لا تزال تشعر بالغثيان أو القئ، أخبر طبيبك أو الممرضة.</p><p>&nbsp;</p><p>إذا إستخدمت حقن زورون&trade; أكثر مما يجب</p><p>سيقوم الطبيب أو الممرضة بإعطائك حقن زورون&trade; ولذلك فمن غير المرجح أن تتلقى أكثر من اللازم. إذا كنت تعتقد أنك قد أعطيت أكثر مما يجب أو فاتتك جرعة، أخبر طبيبك أو الممرضة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>&nbsp;</p><p>4. الآثار الجانبية المحتملة.</p><p>&nbsp;</p><p>مثل جميع الأدوية، قد تتسبب حقن زورون&trade; في بعض الآثار جانبية، إلا أنها لا تصيب جميع الأشخاص</p><p>ردود فعل تحسسية:</p><p>إذا حدثت لك حساسية، أخبر طبيبك أو أحد أفراد الطاقم الطبي على الفور. قد تشمل أعراض الحساسية على:</p><p>&bull; أزيز مفاجئ وألم في الصدر أو ضيق في الصدر</p><p>&bull; تورم الجفون أوالوجه أوالشفاه أو الفم أو اللسان</p><p>&bull; طفح جلدي - بقع حمراء أو كتل تحت الجلد (شرى) في أي مكان على جسمك</p><p>&bull; انهيار.</p><p>&nbsp;</p><p>الآثار الجانبية الأخرى تشتمل على ما يلي:</p><p>شائعة جداً (تؤثر على أكثر من شخص من بين&nbsp; 10 أشخاص)</p><p>&bull; صداع.</p><p>&nbsp;</p><p>شائعة (تؤثر على أقل من شخص من بين&nbsp; 10 أشخاص)</p><p>&bull; شعور بالدفء أو احمرار الوجه&nbsp;&nbsp;&nbsp;&nbsp; &bull; الإمساك</p><p>&bull; تغييرات في نتائج اختبار وظيفة الكبد (إذا كنت تستخدم حقن زورون&trade; مع دواء يسمى سيسپلاتين، و فيما عدا ذلك فإن هذا الآثر الجانبي غير شائع).</p><p>&bull; تهيج واحمرار في موقع الحقن.</p><p>&nbsp;</p><p>غير شائعة (تؤثر على أقل من شخص من بين&nbsp; 100 شخص)</p><p>&bull; الحازوقة&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p>&bull; انخفاض ضغط الدم، من الممكن أن يجعلك تشعر بالدوار أو الإغماء</p><p>&bull; ضربات قلبية غير منتظمة، تباطؤ في ضربات القلب</p><p>&bull; ألم في الصدر &bull; نوبات &bull; حركات جسمانية غير اعتيادية أو رجفه.</p><p>&nbsp;</p><p>نادرة (تؤثر على أقل من شخص من بين&nbsp; 1,000 شخص)</p><p>&bull; شعور بدوار أو خفة في الرأس&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &bull; رؤية غير واضحة</p><p>&bull; اضطراب في ضربات القلب ( مما يتسبب في بعض الأحيان إلي فقدان مفاجئ للوعي)</p><p>&nbsp;</p><p>نادرة جداً (تؤثر على أقل من شخص من بين&nbsp; 10,000 شخص)</p><p>&bull; ضعف الرؤية أو فقدان مؤقت في البصر، عادة ما يعود في غضون 20 دقيقة.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>&nbsp;</p><p>5. كيف تقوم بحفظ حقن زورون&trade;</p><p>&nbsp;</p><p>&nbsp;&bull; يحفظ بعيداً عن متناول و مرأى الأطفال.</p><p>&bull; يحفظ&nbsp; في درجة حرارة لا تزيد عن 03 &ordm;م. يحفظ بعيداً عن الضوء.</p><p>&bull; عند تخفيف حقن زورون&trade; بالسوائل المناسبة للحقن في الوريد:</p><p>&nbsp;&nbsp;&nbsp; - يجب أن يتم حفظها في 2-8 درجة مئوية لمدة لا تزيد على 42 ساعة.</p><p>&nbsp;&nbsp;&nbsp; - لا تحتاج إلى أن تكون محمية من الضوء خلال الحقن في الوريد.</p><p>&nbsp;&bull;لا تستخدم حقن زورون&trade;&nbsp; بعد انتهاء فترة صلاحيتها المكتوب على العلبة وعلى الأمبولة بعد &lsquo;EXP&rsquo;.</p><p>&nbsp;&bull;اسأل الصيدلي عن طريقة التخلص من الأدوية التي لم تعد بحاجة إليها. لا ينبغي التخلص من الأدوية عبر إلقائها فى بالوعات الصرف أو فى مخلفات المنزل . ستساعد هذه التدابير في حماية البيئة</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>&nbsp;</p><p>6. معلومات إضافية</p><p>&nbsp;</p><p>ما هي مكونات حقن زورون&trade;</p><p>&bull; المادة الفعالة هي أوندانسيترون.</p><p>كل أمبولة 2 مل حقن زورون&trade; تحتوي على 4 ملجم أوندانسيترون على هيئة أوندانسيترون هيدروكلورايد دايهيدريت.</p><p>كل أمبولة 4 مل حقن زورون&trade; تحتوي على 8 ملجم أوندانسيترون على هيئة أوندانسيترون هيدروكلورايد دايهيدريت.</p><p>&bull; المكونات الأخرى هي مونوهيدرات حامض الستريك، سترات الصوديوم،</p><p>كلوريد الصوديوم (9 ملجم / مل) و ماء للحقن.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>&nbsp;</p><p>ما هو شكل&nbsp; حقن زورون&trade; وما هي محتوى العبوة:</p><p>حقن زورون&trade; هي سائل رائق عديم اللون.</p><p>&nbsp;</p><p>تتوفر حقن زورون&trade; في:</p><p>&bull; أمبولات زجاجية 2 مل (4 ملجم).</p><p>&bull; أمبولات زجاجية 4 مل (8 ملجم).</p><p>معبأة في عبوة تحتوي 5 أمبولات.</p><p>قد لا تكون كل العبوات مسوقة.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>&nbsp;</p><p>اسم وعنوان مالك رخصة التسويق و المصنع:</p><p>شركة مصنع جمجوم للأدوية، جدة، المملكة العربية السعودية.</p><p>هاتف: 6081111-12-966+&nbsp;&nbsp;&nbsp;&nbsp; فاكس: 6081222-12-966+</p><p>الموقع الإلكتروني: www.jamjoompharma.com</p><p>&nbsp;</p><p>للإبلاغ عن أي أثار جانبيه:</p><p>&nbsp;</p><p>&bull; المملكة العربية السعودية:</p><p>- المركز الوطني للتيقظ و السلامة الدوائية</p><p>&nbsp;&nbsp; o فاكس: 7662-205-11-966+</p><p>&nbsp;&nbsp; o للإتصال بالإدارة التنفيذية للتيقظ وإدارة الأزمات.&nbsp;&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp; هاتف: 2038222-11-966+</p><p>&nbsp;&nbsp;&nbsp;&nbsp; تحويلة:2317-2356-2353-2354-2334-2340</p><p>&nbsp;&nbsp; o الهاتف المجاني: 8002490000&nbsp;&nbsp;</p><p>&nbsp;&nbsp; o بريد إلكتروني:&nbsp; npc.drug@sfda.gov.sa</p><p>&nbsp;&nbsp; o الموقع الالكتروني: www.sfda.gov.sa/npc</p><p>&nbsp;</p><p>&bull; دول الخليج الأخرى:</p><p>- الرجاء الاتصال بالمؤسسات و الهيئات الوطنية في كل دولة</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تم مراجعة هذه النشرة في 12 /2015. رقم النسخة 01
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Zoron 2 mg/ml Injection.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                1 ml solution for injection contains 2 mg ondansetron as ondansetron hydrochloride dihydrate. 
Each ampoule with 2 ml contains 4 mg ondansetron.
Each ampoule with 4 ml contains 8 mg ondansetron. 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Clear and colorless, Solution for injection.


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Ondansetron is indicated for the prevention and treatment of nausea and vomiting induced by cytotoxic chemotherapy and radiotherapy, and for the prevention and treatment of post-operative nausea and vomiting (PONY).</p><p>&nbsp;</p><p><em>Paediatric Population:</em></p><p>Ondansetron is indicated for the management of chemotherapy-induced nausea and vomiting (CINY) in children aged 2&#39;6 months, and for the prevention and treatment of PONY in children aged 2&#39;1 month.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>For intravenous injection or for intravenous infusion after dilution.</p><p>For instructions on dilution of the product before administration, see section 6.6.</p><p>Prescribers intending to use ondansetron in the prevention of delayed nausea and vomiting associated with chemotherapy or radiotherapy in adults, adolescents or children should take into consideration current practice and appropriate guidelines.</p><p>&nbsp;</p><p><u>Chemotherapy and radiotherapy induced nausea and vomiting</u></p><p><em>Adults</em></p><p>The emetogenic potential of cancer treatment varies according to the doses and combinations of chemotherapy and radiotherapy regimens used. The dose range of ondansetron solution for injection or infusion is <u>8-32 mg</u> a day and selected as shown below.</p><p>&nbsp;</p><p><em>Emetogenic chemotherapy and radiotherapy</em></p><p>For patients receiving emetogenic chemotherapy or radiotherapy ondansetron can be given either by intravenous or other routes of administration; however this product is for intravenous use only.</p><p>&nbsp;</p><p>&nbsp;</p><p>The recommended intravenous dose of ondansetron is 8 mg administered as a slow injection (in not less than 30 s econds) or as an infusion over 15 m inutes immediately before treatment, followed by treatment with dosage forms other than intravenous.</p><p>Treatment with dosage forms other than intravenous is recommended to protect against delayed or prolonged emesis after the first 24 hours.</p><p>&nbsp;</p><p><em>Highly emetogenic chemotherapy</em></p><p>For patients receiving highly emetogenic chemotherapy, e.g. high-dose cisplatin, ondansetron can be given by intravenous or other routes of administration; however this product is for intravenous use only.</p><p>&nbsp;</p><p>Ondansetron has been shown to be equally effective in the following intravenous dose schedules over the first 24 hours of chemotherapy:</p><p>&bull;&nbsp; A single dose of 8 mg by slow intravenous injection (in not less than 30 seconds) immediately before chemotherapy.</p><p>&bull;&nbsp;&nbsp; A dose of 8 mg by slow intravenous injection (in not less than 30 seconds) or as a short-time intravenous infusion over 15 minutes immediately before chemotherapy, followed by two further intravenous doses of 8 mg four hours apart, or by a constant infusion of 1 mg/hour for up to 24 hours.</p><p>&bull;&nbsp; A maximum initial intravenous dose of 16 mg diluted in 50-100 ml of sodium chloride 9 mg/ml (0.9 % w/v) solution or other compatible infusion fluid (see compatibility with solutions for infusion under section 6.6) and infused over not less than 15 m inutes immediately before chemotherapy. The initial dose of Ondansetron may be followed by two additional 8 m g intravenous doses (in not less than 30 s econds) four hours apart. A single dose greater than 16 mg must not be given due to dose dependent increase of QT-prolongation risk (see sections 4.4,</p><p>4.8 and 5.1)</p><p>The selection of dose regimen should be determined by the severity of the emetogenic challenge. The efficacy of ondansetron in highly emetogenic chemotherapy may be enhanced by the addition of a single intravenous dose of dexamethasone sodium phosphate, 20 mg administered prior to chemotherapy.</p><p>To protect against delayed or prolonged emesis after the first 24 hours, ondansetron treatment with dosage forms other than intravenous should be continued after a course of treatment.</p><p>&nbsp;</p><p><em>Paediatric Population:</em></p><p>CINY in children aged 2&#39; 6 months and adolescents</p><p>The dose for CINY can be calculated based on body surface area (BSA) or weight - see below. Weight-based dosing results in higher total daily doses compared to BSA-based dosing (see sections 4.4.and 5.1).</p><p>&nbsp;</p><p>Ondansetron injection should be diluted in 5% glucose or 0.9% sodium chloride or other compatible infusion fluid (see section 6.6) and infused intravenously over not less than 15 minutes. There are no data from controlled clinical trials on t he use of Ondansetron in the</p><p>&nbsp;</p><p>prevention of delayed or prolonged CINY. There are no data from controlled clinical trials on the use of Ondansetron for radiotherapy-induced nausea and vomiting in children.</p><p>Dosing by BSA:</p><p>Ondansetron should be administered immediately before chemotherapy as a single intravenous dose of 5 mg/m<sup>2</sup>. The intravenous dose must not exceed 8 mg.</p><p>Oral dosing can commence twelve hours later and may be continued for up to 5 days (Table 1). The total daily dose must not exceed adult dose of 32 mg.</p><p>Table 1: BSA-based dosing for Chemotherapy - Children aged 2&#39;6 months and adolescents</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>BSA</p></td><td style="vertical-align:top"><p>Day 1(a,b)</p></td><td style="vertical-align:top"><p>Days 2-6<sup>(b)</sup></p></td></tr><tr><td style="vertical-align:top"><p>&lt; 0.6 m<sup>2</sup></p></td><td style="vertical-align:top"><p>5 mg/m<sup>2</sup> i.v. plus 2 mg syrup after 12 hrs</p></td><td style="vertical-align:top"><p>2 mg syrup every 12 hrs</p></td></tr><tr><td style="vertical-align:top"><p>2&#39; 0.6 m<sup>2</sup></p></td><td style="vertical-align:top"><p>5 mg/m<sup>2</sup> i.v. plus 4 mg syrup or tablet after 12 hrs</p></td><td style="vertical-align:top"><p>4 mg syrup or tablet every 12 hrs</p></td></tr></tbody></table><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The intravenous dose must not exceed 8mg.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The total daily dose must not exceed adult dose of 32 mg</p><p>Dosing by bodyweight:</p><p>Weight-based dosing results in higher total daily doses compared to BSA-based dosing (see sections 4.4. and 5.1).</p><p>&nbsp;</p><p>Ondansetron should be administered immediately before chemotherapy as a single intravenous dose of 0.15 mg/kg. The intravenous dose must not exceed 8 mg. Two further intravenous doses may be given in 4-hourly intervals. The total daily dose must not exceed adult dose of 32 mg.</p><p>&nbsp;</p><p>Oral dosing can commence twelve hours later and may be continued for up to 5 days (Table 2). Table 2: Weight-based dosing for Chemotherapy - Children aged 2&#39;6 months and adolescents</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Weight</p></td><td style="vertical-align:top"><p>Day 1 (a,b)</p></td><td style="vertical-align:top"><p>Days 2-6<sup>(b)</sup></p></td></tr><tr><td style="vertical-align:top"><p>:S 10 kg</p></td><td style="vertical-align:top"><p>Up to 3 dos es of 0.15 mg/kg every 4 hrs</p></td><td style="vertical-align:top"><p>2 mg syrup every 12 hrs</p></td></tr><tr><td style="vertical-align:top"><p>&gt; 10 kg</p></td><td style="vertical-align:top"><p>Up to 3 dos es of 0.15 mg/kg every 4 hrs</p></td><td style="vertical-align:top"><p>4 mg syrup or tablet every 12 hrs</p></td></tr></tbody></table><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The intravenous dose must not exceed 8mg.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The total daily dose must not exceed adult dose of 32 mg.</p><p>&nbsp;</p><p>&nbsp;</p><p><em>Elderly</em></p><p>In patients 65 to 74 years of age, the dose schedule for adults can be followed. All intravenous doses should be diluted in 50-100 ml of saline or other compatible infusion fluid (see section 6.6) and infused over 15 minutes.</p><p><!--[if gte vml 1]><v:shape
 id="_x0000_s1026" style='position:absolute;left:0;text-align:left;
 margin-left:69.25pt;margin-top:68.05pt;width:470.9pt;height:13.8pt;z-index:-251658240;
 mso-position-horizontal-relative:page;mso-position-vertical-relative:text'
 coordsize="9418,276" o:allowincell="f" path="m,275hhl9417,275,9417,,,,,275xe"
 stroked="f">
 <v:path arrowok="t"/>
 <w:wrap anchorx="page"/>
</v:shape><![endif]--><img width="628" height="19" src="file:///C:/Users/HAFIZ~1.KHA/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png" />In patients 75 years of age or older, the initial intravenous dose should not exceed 8 mg. All intravenous doses should be diluted in 50-100 ml of saline or other compatible infusion fluid (see section 6.6) and infused over 15 m inutes. The initial dose of 8 m g may be followed by two further intravenous doses of 8 mg, infused over 15 m inutes and given no l ess than four hours apart (see section 5.2).</p><p>Please refer also to &quot;Special Populations&quot;.</p><p>&nbsp;</p><p><u>Post-operative nausea and vomiting (PONY)</u></p><p><em>Prevention of PONV</em></p><p><em>Adults: </em>For the prevention of PONY ondansetron can be administered by intravenous injection or other dosage forms.</p><p>Ondansetron may be administered as a single dose of 4 mg given by slow intravenous injection at induction of anaesthesia.</p><p><em>Treatment of established PONV</em></p><p>For treatment of established PONY a single dose of 4 mg given by slow intravenous injection is recommended.</p><p><em>Pediatric population</em></p><p><em>PONV in children aged </em>2&#39; <em>1 month and adolescents</em></p><p>For prevention of PONY in pediatric patients having surgery performed under general anaesthesia, a single dose of ondansetron may be administered by slow intravenous injection (not less than 30 seconds) at a dose of 0.1 mg/kg up to a maximum of 4 mg either prior to, at or after induction of anaesthesia.</p><p>For the treatment of PONY after surgery in pediatric patients having surgery performed under general anaesthesia, a single dose of ondansetron may be administered by slow intravenous injection (not less than 30 seconds) at a dose of 0.1 mg/kg up to a maximum of 4 mg. There are no data on the use of ondansetron in the treatment of PONY in children below 2 years of age.</p><p>For treatment of established PONY in pediatric patients and adolescents, ondansetron may be administered by slow intravenous injection at a dose of 0.1 mg/kg up to a maximum of 4 mg.</p><p>There is limited data on the use of ondansetron in the prevention and treatment of PONY in children under 2 years of age.</p><p><em>Elderly</em></p><p>There is limited experience in the use of ondansetron in the prevention and treatment of PONY in the elderly, however ondansetron is well tolerated in patients over 65 years receiving chemotherapy.</p><p>Please refer also to &quot;Special Populations&quot;. <u>Special Populations</u></p><p><em>Patients with renal impairment</em></p><p>No alteration of daily dosage or frequency of dosing, or route of administration is required.</p><p><em>Patients with hepatic impairment</em></p><p>&nbsp;</p><p><em>&nbsp;</em></p><p>Clearance of ondansetron is significantly reduced and serum half life significantly prolonged in subjects with moderate or severe impairment of hepatic function. In such patients a total daily dose of 8 mg should not be exceeded.</p><p><em>Patients with poor sparteine/debrisoquine metabolism</em></p><p>The elimination half-life of ondansetron is not altered in subjects classified as poor metabolisers of sparteine and debrisoquine. Consequently in such patients repeat dosing will give drug exposure levels no different from those of the general population. No alteration of daily dosage or frequency of dosing is required.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to other selective 5-HT3 receptor antagonists (e.g. granisetron, dolasetron) or to any of the excipients listed in section 6.1.
Based on reports of profound hypotension and loss of consciousness when ondansetron was administered with apomorphine hydrochloride, concomitant use with apomorphine is contraindicated.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Hypersensitivity reactions have been reported in patients who have exhibited hypersensitivity to other selective 5-HT<sub>3</sub> receptor antagonists.</p><p>Respiratory events should be treated symptomatically and clinicians should pay particular attention to them as precursors of hypersensitivity reactions.</p><p>Ondansetron prolongs the QT interval in a dose-dependent manner (see section 5.1). In addition, post-marketing cases of Torsade de Pointes have been reported in patients using ondansetron. Avoid ondansetron in patients with congenital long QT syndrome. Ondansetron should be administered with caution to patients who have or may develop prolongation of QTc. These conditions include patients with electrolyte abnormalities, congestive heart failure, bradyarrhythmias or patients taking other medicinal products that lead to QT prolongation or electrolyte abnormalities.</p><p>Hypokalaemia and hypomagnesaemia should be corrected prior to ondansetron administration. There have been post-marketing reports describing patients with serotonin syndrome (including altered mental status, autonomic instability and neuromuscular abnormalities) following the concomitant use of ondansetron and other serotonergic drugs (including selective serotonin reuptake inhibitors (SSRI) and serotonin noradrenaline reuptake inhibitors (SNRIs)). If concomitant treatment with ondansetron and other serotonergic drugs is clinically warranted, appropriate observation of the patient is advised.</p><p>As ondansetron is known to increase large bowel transit time, patients with signs of subacute intestinal obstruction should be monitored following administration.</p><p>In patients with adenotonsillar surgery prevention of nausea and vomiting with ondansetron may mask occult bleeding. Therefore, such patients should be followed carefully after ondansetron.</p><p><em>Paediatric Population:</em></p><p>Paediatric patients receiving ondansetron with hepatotoxic chemotherapeutic agents should be monitored closely for impaired hepatic function.</p><p>&nbsp;</p><p>&nbsp;</p><p>CINY</p><p>When calculating the dose on an mg/kg basis and administering three doses at 4-hourly intervals, the total daily dose will be higher than if one single dose of 5mg/m<sup>2</sup> followed by an oral dose is given. The comparative efficacy of these two different dosing regimens has not been investigated in clinical trials. Cross-trial comparison indicates similar efficacy for both regimens (section5.1). This medicinal product contains 2.3 mmol (or 53.5 mg) sodium per 32 mg dose. To be taken into consideration by patients on a controlled sodium diet.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Effects of ondansetron on other medicinal products</u></p><p>There is no e vidence that ondansetron either induces or inhibits the metabolism of other drugs commonly co-administered with it. Specific studies have shown that ondansetron does not interact with alcohol, temazepam, furosemide, alfentanil, morphine, lignocaine, propofol and thiopental.</p><p>&nbsp;</p><p><u>Effects of other medicinal products on ondansetron</u></p><p>Ondansetron is metabolised by multiple hepatic cytochrome P-450 enzymes: CYP3A4, CYP2D6 and CYP1A2. Due to the multiplicity of metabolic enzymes capable of metabolising ondansetron, enzyme inhibition or reduced activity of one enzyme (e. g. CYP2D6 genetic deficiency) is normally compensated by other enzymes and should result in little or no significant change in overall ondansetron clearance or dose requirement.</p><p>Caution should be exercised when ondansetron is co-administered with drugs that prolong the QT interval and/or cause electrolyte abnormalities (see section 4.4).</p><p>Use of ondansetron with QT prolonging drugs may result in additional QT prolongation. Concomitant use of ondansetron with cardiotoxic drugs (e.g. anthracyclines such as doxorubicin, daunorubicin or trastuzimab), antibiotics (such as erythromycin or ketoconazole), antiarrhythmics (such as amiodarone) and beta blockers (such as atenolol or timolol) may increase the risk of arrhythmias (see section 4.4).</p><p>There have been post-marketing reports describing patients with serotonin syndrome (including altered mental status, autonomic instability and neuromuscular abnormalities) following the concomitant use of ondansetron and other serotonergic drugs (including SSRIs and SNRIs) (see section 4.4).</p><p><em>Apomorphine</em>: Based on reports of profound hypotension and loss of consciousness when ondansetron was administered with apomorphine hydrochloride, concomitant use with apomorphine is contraindicated.</p><p><em>Phenytoin, carbamazepine and rifampicin</em>: In patients treated with potent inducers of CYP3A4&nbsp; (i. e. phenytoin, carbamazepine and rifampicin), the oral clearance of ondansetron was increased and ondansetron blood concentrations were decreased.</p><p><em>Tramadol</em>: Data from small studies indicate that ondansetron may reduce the analgesic effect of tramadol.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy:</u></p><p>To date, the safe use of ondansetron during pregnancy has not been established.</p><p>Evaluation of experimental animal studies does not indicate direct or indirect harmful effects with respect to the development of the embryo, or fetus, the course of gestation and peri- and post-natal development.</p><p>However, as animal studies are not always predictive of human response, the use of ondansetron in pregnancy is not recommended.</p><p><u>Lactation:</u></p><p>Tests have shown that ondansetron passes into the milk of lactating animals (see section 5.3). It is therefore recommended that mothers receiving ondansetron should not breast-feed their babies.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Ondansetron 2 mg/ml has no or negligible influence on the ability to drive and use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The following frequency terminology is used:</p><p>Yery common: 2&#39;1/10; Common: 2&#39;1/100 to &lt;1/10;</p><p>Uncommon: 2&#39;1/1,000 to &lt;1/100; Rare: 2&#39;1/10,000 to &lt;1/1,000;</p><p>Yery rare: &lt;1/10,000;</p><p>Not known: cannot be established from the available data</p><p><u>Immune system disorders</u></p><p>Rare:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Immediate hypersensitivity reactions, sometimes severe including anaphylaxis. Anaphylaxis may be fatal.</p><p>Hypersensitivity reactions were also observed in patients, who were sensitive towards other selective 5-HT<sub>3</sub> receptor antagonists.</p><p><u>Nervous system disorders</u> Yery common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Headache.</p><p>Uncommon: There have been reports suggestive of&nbsp; involuntary&nbsp; movement&nbsp; disorders such as extrapyramidal reactions, e.g. oculogyric crisis/dystonic reactions and dyskinesia without definitive evidence of persistent clinical sequelae and seizures (e.g. epileptic spasms) have been observed although no know n pharmacological mechanism can account for ondansetron causing these effects.</p><p>Rare:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dizziness during rapid intravenous administration. Yery rare:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Depression.</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Eye disorders</u></p><p>Rare:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Transient visual disturbances (e.g. blurred vision) during rapid intravenous administration.</p><p>Yery rare:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In individual cases transitory blindness was reported in patients receiving chemotherapeutic agents including cisplatin. Most reported cases were resolved within 20 m inutes. Some cases of transient blindness were reported as cortical in origin.</p><p><u>Cardiac disorders</u></p><p>Uncommon: Chest pain with or without ST&nbsp; segment&nbsp; depression,&nbsp; cardiac arrhythmias and bradycardia. Chest pain and cardiac arrhythmias may be fatal in individual cases.</p><p>Rare:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Transitory changes in the electrocardiogram, QTc prolongation (including Torsades de Pointes)</p><p><u>Yascular disorders</u></p><p>Common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sensations of flushing or warmth. Uncommon:&nbsp;&nbsp; Hypotension.</p><p><u>Respiratory, thoracic and mediastinal disorders</u> Uncommon:&nbsp; Hiccups.</p><p><u>Gastrointestinal disorders</u></p><p>Common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Ondansetron is known to increase the large bowel transit time and may cause constipation in some patients.</p><p><u>Hepatobiliary disorders</u></p><p>Uncommon: Asymptomatic&nbsp; increases&nbsp; in&nbsp; liver&nbsp; function&nbsp; tests&nbsp; were&nbsp; observed. These reactions were frequently observed in patients under chemotherapy with cisplatin.</p><p><u>Skin and subcutaneous tissue disorders</u></p><p>Uncommon: Hypersensitivity reactions around the injection site&nbsp; (e.g.&nbsp; rash,&nbsp; urticaria, itching) may occur, sometimes extending along the drug administration vein.</p><p><u>General disorders and administration site conditions</u> Common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Local reactions at the IY injection site. <u>Pediatric population</u></p><p>The adverse event profile in children and adolescents was comparable to that seen in</p><p>adults.</p><p><u>Reporting of suspected adverse reactions</u></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme Website: www.mhra.gov.uk/yellowcard</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Little is known at present about overdosage with ondansetron, however, a limited number of patients received overdoses. In the majority of cases, symptoms were similar to those already reported in patients receiving recommended doses (see section 4.8). Manifestations that have been reported include visual disturbances, severe constipation, hypotension and a vasovagal episode with transient second degree AY block. In all instances, the events resolved completely. Ondansetron prolongs the QT interval in a dose-dependent fashion. ECG monitoring is recommended in cases of overdose.</p><p>There is no s pecific antidote for ondansetron, therefore in all cases of suspected overdose, symptomatic and supportive therapy should be given as appropriate. The use of ipecacuanha to treat overdose with ondansetron is not recommended, as patients are unlikely to respond due to the anti-emetic action of ondansetron itself.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Antiemetics and antinauseants, Serotonin (5HT<sub>3</sub>) antagonists ATC Code: A04AA01</p><p>Ondansetron is a potent, highly selective 5HT<sub>3</sub> receptor-antagonist.</p><p>Its precise mode of action in the control of nausea and vomiting is not known. Chemotherapeutic agents and radiotherapy may cause release of 5HT in the small intestine initiating a vomiting reflex by activating vagal afferents via 5HT<sub>3</sub> receptors. Ondansetron blocks the initiation of this reflex. Activation of vagal afferents may also cause a r elease of 5HT in the area postrema, located on the floor of the fourth ventricle, and this may also promote emesis through a central mechanism. Thus, the effect of ondansetron in the management of the nausea and vomiting induced by cytotoxic chemotherapy and radiotherapy is probably due to antagonism of 5HT<sub>3</sub> receptors on neurons located both in the peripheral and central nervous system. The mechanisms of action in post-operative nausea and vomiting are not known but there may be common pathways with cytotoxic induced nausea and vomiting.</p><p>Ondansetron does not alter plasma prolactin concentrations. The role of ondansetron in opiate- induced emesis is not yet established.</p><p>The effect of ondansetron on t he QTc interval was evaluated in a double blind, randomised, placebo and positive (moxifloxacin) controlled, crossover study in 58 healthy adult men and women. Ondansetron doses included 8 mg and 32 mg infused intravenously over 15 minutes. At the highest tested dose of 32 mg, the maximum mean (upper limit of 90% CI) difference in QTcF from placebo after baseline-correction was 19.6 ( 21.5) msec. At the lower tested dose of 8 mg, the maximum mean (upper limit o f 90% CI) difference in QTcF from placebo after baseline- correction was 5.8 (7.8) msec. In this study, there were no QTcF measurements greater than 480 msec and no QTcF prolongation was greater than 60 msec. No significant changes were seen in the measured electrocardiographic PR or QRS intervals.</p><p>&nbsp;</p><p>&nbsp;</p><p><strong><em>Paediatric population</em></strong></p><p>CINY</p><p>The efficacy of ondansetron in the control of emesis and nausea induced by cancer chemotherapy was assessed in a double-blind randomised trial in 415 patients aged 1 to 18 years (S3AB3006). On the days of chemotherapy, patients received either Ondansetron 5 mg/m2 intravenous + ondansetron 4 mg orally after 8-12 hrs or ondansetron 0.45 mg/kg intravenous + placebo orally after 8-12 hrs. Post- chemotherapy both groups received 4 mg ondansetron syrup twice daily for</p><p>3 days. Complete control of emesis on w orst day of chemotherapy was 49% (5 mg/m2 intravenous + ondansetron 4 m g orally) and 41% (0.45 mg/kg intravenous + placebo orally). Post-chemotherapy both groups received 4 mg ondansetron syrup twice daily for 3 days.</p><p>A double-blind randomised placebo-controlled trial (S3AB4003) in 438 patients aged 1 t o 17 years demonstrated complete control of emesis on worst day of chemotherapy in:</p><p>&bull;&nbsp;&nbsp;&nbsp; 73% of patients when ondansetron was administered intravenously at a dose of 5 mg/m<sup>2</sup> intravenous together with 2-4 mg dexamethasone orally</p><p>&bull;&nbsp;&nbsp; 71% of patients when ondansetron was administered as syrup at a dose of 8 mg + 2-4 mg dexamethasone orally on the days of chemotherapy.</p><p>Post-chemotherapy both groups received 4 mg ondansetron syrup twice daily for 2 days.</p><p>The efficacy of ondansetron in 75 children aged 6 to 48 months was investigated in an openlabel, non-comparative, single-arm study (S3A40320). All children received three 0.15 mg/kg doses of intravenous ondansetron, administered 30 minutes before the start of chemotherapy and then at four and eight hours after the first dose. Complete control of emesis was achieved in 56% of patients.</p><p>Another open-label, non-comparative, single-arm study (S3A239) investigated the efficacy of one intravenous dose of 0.15 mg/kg ondansetron followed by two oral ondansetron doses of 4 mg for children aged &lt; 12 yrs and 8 mg for children aged 2&#39; 12 yrs (total no. of children n= 28). Complete control of emesis was achieved in 42% of patients.</p><p>PONY</p><p>The efficacy of a single dose of ondansetron in the prevention of post-operative nausea and vomiting was investigated in a randomised, double-blind, placebo-controlled study in 670 children aged 1 to 24 months (post-conceptual age 2&#39;44 weeks, weight 2&#39; 3 kg). Included subjects were scheduled to undergo elective surgery under general anaesthesia and had an ASA status :S</p><p>III. A single dose of ondansetron 0.1 m g/kg was administered within five minutes following induction of anaesthesia. The proportion of subjects who experienced at least one emetic episode during the 24-hour assessment period (ITT) was greater for patients on placebo than those receiving ondansetron ((28% vs. 11%, p &lt;0.0001).</p><p>Four double-blind, placebo-controlled studies have been performed in 1469 male and female patients (2 to 12 years of age) undergoing general anaesthesia. Patients were randomised to&nbsp; either single intravenous doses of ondansetron (0.1 mg/kg for paediatric patients weighing 40 kg or less, 4 mg for paediatric patients weighing more than 40 kg ; number of patients = 735)) or placebo (number of patients = 734). Study drug was administered over at least 30 s econds, immediately prior to or following anaesthesia induction. Ondansetron was significantly more effective than placebo in preventing nausea and vomiting. The results of these studies are summarised in Table 3.</p><p>&nbsp;</p><p>&nbsp;</p><p>Table 3 Prevention and treatment of PONY in Paediatric Patients - Treatment response over</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Study</p></td><td style="vertical-align:top"><p>Endpoint</p></td><td style="vertical-align:top"><p>Ondansetron %</p></td><td style="vertical-align:top"><p>Placebo %</p></td><td style="vertical-align:top"><p>p value</p></td></tr><tr><td style="vertical-align:top"><p>S3A380</p></td><td style="vertical-align:top"><p>CR</p></td><td style="vertical-align:top"><p>68</p></td><td style="vertical-align:top"><p>39</p></td><td style="vertical-align:top"><p>:S 0.001</p></td></tr><tr><td style="vertical-align:top"><p>S3GT09</p></td><td style="vertical-align:top"><p>CR</p></td><td style="vertical-align:top"><p>61</p></td><td style="vertical-align:top"><p>35</p></td><td style="vertical-align:top"><p>:S 0.001</p></td></tr><tr><td style="vertical-align:top"><p>S3A381</p></td><td style="vertical-align:top"><p>CR</p></td><td style="vertical-align:top"><p>53</p></td><td style="vertical-align:top"><p>17</p></td><td style="vertical-align:top"><p>:S 0.001</p></td></tr><tr><td style="vertical-align:top"><p>S3GT11</p></td><td style="vertical-align:top"><p>no nausea</p></td><td style="vertical-align:top"><p>64</p></td><td style="vertical-align:top"><p>51</p></td><td style="vertical-align:top"><p>0.004</p></td></tr><tr><td style="vertical-align:top"><p>S3GT11</p></td><td style="vertical-align:top"><p>no emesis</p></td><td style="vertical-align:top"><p>60</p></td><td style="vertical-align:top"><p>47</p></td><td style="vertical-align:top"><p>0.004</p></td></tr></tbody></table><p>CR = no emetic episodes, rescue or withdrawal</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The pharmacokinetic properties of ondansetron are unchanged on repeat dosing.</p><p>A direct correlation of plasma concentration and anti-emetic effect has not been established. <u>Absorption</u></p><p>Following oral administration, ondansetron is passively and completely absorbed from the gastrointestinal tract and undergoes first pass metabolism (Bioavailability is about 60%.). Peak plasma concentrations of about 30 n g/ml are attained approximately 1.5 hours after an 8 mg dose. For doses above 8 mg the increase in ondansetron systemic exposure with dose is greater than proportional; this may reflect some reduction in first pass metabolism at higher oral doses. Bioavailability, following oral administration, is slightly enhanced by the presence of food but unaffected by antacids.</p><p>A 4 m g intravenous infusion of ondansetron given over 5 m inutes results in peak plasma concentrations of about 65 ng/ml. Following intramuscular administration of ondansetron, peak plasma concentrations of about 25 ng/ml are attained within 10 minutes of injection.</p><p><u>Distribution</u></p><p>The disposition of ondansetron following oral, intramuscular (IM) and intravenous (IY) dosing is similar with a steady state volume of distribution of about 140 L. Equivalent systemic exposure is achieved after IM and IY administration of ondansetron.</p><p>Ondansetron is not highly protein bound (70-76%). <u>Metabolism</u></p><p>Ondansetron is cleared from the systemic circulation predominantly by hepatic metabolism through multiple enzymatic pathways. The absence of the enzyme CYP2D6 (the debrisoquine polymorphism) has no effect on ondansetron&#39;s pharmacokinetics.</p><p><u>Excretion</u></p><p>Less than 5% of the absorbed dose is excreted unchanged in the urine. Terminal half life is about 3 hours.</p><p><u>Special Patient Populations</u></p><p><em>Children and Adolescents (aged 1 month to 17 years)</em></p><p>In paediatric patients aged 1 t o 4 m onths (n=19) undergoing surgery, weight normalised clearance was approximately 30% slower than in patients aged 5 t o 24 m onths (n=22) but comparable to the patients aged 3 to 12 years. The half-life in the patient population aged 1 to 4</p><p>&nbsp;</p><p>months was reported to average 6.7 hours compared to 2.9 hours for patients in the 5 to 24 month and 3 to 12 year age range. The differences in pharmacokinetic parameters in the 1 to 4 month patient population can be explained in part by the higher percentage of total body water in neonates and infants and a higher volume of distribution for water soluble drugs like ondansetron.</p><p>In a study of 21 pa ediatric patients aged between 3 a nd 12 years undergoing elective surgery with general anaesthesia, the absolute values for both the clearance and volume of distribution of ondansetron following a single intravenous dose of 2 mg (3-7 years old) or 4 mg (8-12 years old) were reduced. The magnitude of the change was age-related, with clearance falling from about 300 ml/min at 12 years of age to 100 ml/min at 3 years. Yolume of distribution fell from about 75 L at 12 years to 17 L at 3 years. Use of weight-based dosing (0.1 mg/kg up t o 4 m g maximum) compensates for these changes and is effective in normalising systemic exposure in paediatric patients.</p><p>Based on t he population pharmacokinetic parameters for subjects aged 1 month to 48 months, administration of a 0.15 mg/kg i.v. dose of ondansetron every 4 hours for 3 doses would result in a systematic exposure (AUC) comparable to that observed in paediatric surgery subjects aged 5 to 24 months and previous paediatric studies in cancer (aged 4 to 18 years) and surgical (aged 3 to 12 years) subjects, at similar doses.</p><p>Population pharmacokinetic analysis was performed on 428 s ubjects (cancer patients, surgery patients and healthy volunteers) aged 1 month to 44 years following intravenous administration of ondansetron. Based on this analysis, systemic exposure (AUC) of ondansetron following oral or IY dosing in children and adolescents was comparable to adults, with the exception of infants aged 1 t o 4 m onths. Yolume was related to age and was lower in adults than in infants and children. Clearance was related to weight but not to age with the exception of infants aged 1 to 4 months. It is difficult to conclude whether there was an additional reduction in clearance related to age in infants 1 to 4 months or simply inherent variability due to the low number of subjects studied in this age group. Since patients less than 6 months of age will only receive a single dose in PONY a decreased clearance is not likely to be clinically relevant.</p><p><em>Elderly persons</em></p><p>Studies in healthy elderly volunteers have shown slight age-related increases in both oral bioavailability (65%) and half-life (5 hours).</p><p><em>Renal impairment</em></p><p>In patients with renal impairment (creatinine clearance 15-60 ml/min), both systemic clearance and volume of distribution are reduced following IY administration of ondansetron, resulting in a slight, but clinically insignificant, increase in elimination half-life (5.4 h). A study in patients with severe renal impairment who required regular haemodialysis (studied between dialyses) showed ondansetron&#39;s pharmacokinetics to be essentially unchanged following IY administration.</p><p><em>Hepatic impairment</em></p><p>Following oral, intravenous or intramuscular dosing in patients with severe hepatic impairment, ondansetron&#39;s systemic clearance is markedly reduced with prolonged elimination half-lives (15- 32 h) and an oral bioavailability approaching 100% due to reduced pre-systemic metabolism.</p><p>&nbsp;</p><p>&nbsp;</p><p><em>Gender differences</em></p><p>Gender differences were shown in the disposition of ondansetron, with females having a greater rate and extent of absorption following an oral dose and reduced systemic clearance and volume of distribution (adjusted for weight).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Preclinical data revealed no special hazard for humans based on conventional studies of safety, pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential and toxicity to reproduction.</p><p>Ondansetron and its metabolites accumulate in the milk of rats, milk/plasma-ratio was 5.2:1.</p><p>A study in cloned human cardiac ion channels has shown ondansetron has the potential to affect cardiac repolarisation via blockade of HERG potassium channels. The clinical relevance of this finding is uncertain.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sodium chloride</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sodium citrate</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Citric acid monohydrate</p><p>Water for injections</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>This medicinal product must not be mixed with other medicinal products except those mentioned in section 6.6.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 Months (Unopened)
24 Hours (Dilution stored in 2-8C)

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30C. Protect from light.</p><p>Dilution of Ondansetron Injection in compatible intravenous infusion fluids are stable under room lighting condition or daylight for at least 24 hours, thus no protection from light is necessary while infusion takes place.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&bull;&nbsp; 2 ml (4 mg) glass ampoules.</p><p>&bull;&nbsp; 4 ml (8 mg) glass</p><p>Packed in boxes of 5 ampules. Not all packs may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The solution is to be visually inspected prior to use (also after dilution). Only clear solutions practically free from particles should be used.</p><p>Any unused product or waste material should be disposed of in accordance with local requirements.</p><p>Ondansetron 2 mg/ml may be diluted with the following solutions for infusion to concentrations of ondansetron as stated in section 4.2:</p><p>Sodium chloride 9 mg/ml (0.9 % w/v) solution Glucose 50 mg/ml (5 % w/v) solution Mannitol 100 mg/ml (10 % w/v) solution Ringer&#39;s lactate solution</p><p>The diluted solutions should be stored protected from light. Note:</p><p>The solution for injection must not be sterilized in an autoclave!</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Jamjoom Pharmaceuticals Company
Plot No. ME 1:3, Phase Y, Industrial City, Jeddah Postal address:
P.O. Box 6267
Jeddah 21442, Saudi Arabia. Tel: 00966-12-6081111
Fax: 00966-12-6081222
E-mail: jpharma@jamjoompharma.com Website: www.jamjoompharma.com

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Not Applicable since this is an initial application for submission.
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>